Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension

Am J Respir Crit Care Med. 2023 Dec 1;208(11):1248. doi: 10.1164/rccm.202308-1347LE.

Authors

Taro Yasuma¹, Hajime Fujimoto², Corina N D'Alessandro-Gabazza¹, Esteban C Gabazza¹, Osamu Hataji³, Tetsu Kobayashi²

Affiliations

¹ Department of Immunology and.
² Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Japan; and.
³ Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.

No abstract available

Publication types

Letter

MeSH terms

Antihypertensive Agents / pharmacology
Antihypertensive Agents / therapeutic use
Epoprostenol* / pharmacology
Epoprostenol* / therapeutic use
Familial Primary Pulmonary Hypertension / drug therapy
Humans
Pulmonary Arterial Hypertension* / drug therapy
T-Lymphocytes, Regulatory
Treatment Outcome

Substances

treprostinil
Epoprostenol
Antihypertensive Agents